List of Excipients in Branded Drug CALCIPOTRIENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	.ALPHA.-TOCOPHEROL, DL-
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	CETYL ALCOHOL
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	EDETATE DISODIUM
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	ISOPROPYL MYRISTATE
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	LIGHT MINERAL OIL
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	PETROLATUM
Mayne Pharma	CALCIPOTRIENE	calcipotriene	51862-512	POLYOXYL 20 CETOSTEARYL ETHER

Generic Drugs Containing CALCIPOTRIENE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	HYDROXYPROPYL CELLULOSE
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	ISOPROPYL ALCOHOL
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	MENTHOL
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	PROPYLENE GLYCOL
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	SODIUM CITRATE
Amneal Pharmaceuticals of New York LLC	calcipotriene	0115-1475	WATER
Fougera Pharmaceuticals Inc	calcipotriene	0168-0400	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in CALCIPOTRIENE?

# Of NDCs	Excipient
3	.ALPHA.-TOCOPHEROL
3	BENZYL ALCOHOL
5	CETETH-20
5	CETOSTEARYL ALCOHOL
2	DIAZOLIDINYL UREA
2	DICHLOROBENZYL ALCOHOL
5	EDETATE DISODIUM

Excipient Strategy and Commercial Opportunities for Calcipotriol

Last updated: March 1, 2026

What is the excipient strategy for Calcipotriol?

Calcipotriol, a vitamin D analogue used primarily for psoriasis treatment, employs specific excipients to optimize stability, bioavailability, and patient compliance. Its formulation often involves the following excipients:

• Propylene glycol: Enhances solubility and penetration.
• Petrolatum or ointment base: Provides occlusion and sustained release.
• Ethanol: Used in solutions to improve solubility.
• Petrolatum and mineral oil: Common in topical ointments for lubrication and stability.
• Emulsifiers: Facilitate formulation stability in cream formulations.

These excipients are selected based on their ability to stabilize the active compound and ensure consistent delivery. The choice varies across formulations such as ointments, gels, and solutions.

How do excipients impact formulation stability and efficacy?

Excipients influence critical parameters:

• Chemical stability: Certain excipients prevent oxidative degradation of calcipotriol.
• Permeability: Propylene glycol enhances transdermal penetration.
• Patient compliance: Non-greasy, easily absorbed formulations with suitable excipients improve usability.
• Shelf life: Excipients like antioxidants extend product shelf life by preventing oxidation.

What are the clinical and commercial implications?

Selecting the right excipients allows for multi-derivative formulations, including:

• Topical ointments and creams: Largest market segment.
• Solutions and gels: For rapid absorption.
• Combination products: Incorporate corticosteroids alongside calcipotriol once excipient compatibility is confirmed.

Patent strategies often include specific excipient combinations, creating barriers for generic entry and extending exclusivity.

What commercial opportunities exist for excipient innovation?

Opportunities include:

• Novel excipients: Biodegradable, non-irritant agents that enhance delivery or reduce manufacturing costs.
• Formulation enhancements: Emulsifiers that improve stability at higher temperatures could expand shelf life.
• Personalized formulations: Tailoring excipients based on patient demographics or disease severity.

Development of patent-protected excipient combinations could provide competitive differentiation. As patents for core active ingredients expire, excipient patents can prolong market exclusivity.

Industry landscape and regulatory considerations

Regulatory agencies, such as the FDA and EMA, scrutinize excipient safety and compatibility. Innovators should document excipient functionality thoroughly. Their strategies should include:

• GRAS (Generally Recognized as Safe) status: For new excipients.
• Stability data: To support shelf life extension claims.
• Bioavailability studies: Confirming excipient impact on absorption.

Key patent trends

• Formulation patents: Cover specific excipient combinations or delivery modes.
• Method-of-use patents: Encompass novel excipient-enhanced delivery methods.
• Excipients patents: Cover new ingredients with multifunctional roles.

Market size and growth potential

The global psoriasis treatment market was valued at approximately USD 8.3 billion in 2021. Calcipotriol accounts for significant share within topical vitamin D analogs, with growth driven by:

• Increasing prevalence of psoriasis.
• Demand for topical, steroid-sparing therapies.
• Innovations in formulation technology.

The topical psoriasis segment is projected to grow at a CAGR of 4.2% from 2022 to 2027 (Grand View Research, 2022).

---

Key Takeaways

• Excipients in calcipotriol formulations include penetration enhancers, stabilizers, and bases — selected to optimize stability and bioavailability.
• Innovation in excipient chemistry offers commercial opportunities via extended patent protection and new product differentiation.
• Regulatory considerations focus on safety and stability testing, essential to validate excipient roles.
• The evolving market for psoriasis therapies emphasizes topical formulations, presenting ongoing opportunities for excipient innovation.

---

FAQs

1. What are the main challenges in excipient selection for calcipotriol formulations?
Ensuring chemical stability, maximizing skin absorption, avoiding irritation, and meeting regulatory requirements are key challenges.

2. Can new excipients extend the patent life of calcipotriol products?
Yes, patents on novel excipient combinations or formulations can extend exclusivity beyond the original active ingredient patents.

3. How do excipients influence the safety profile of topical calcipotriol?
Excipients must be non-irritant, non-allergenic, and safe for long-term skin contact, complying with regulatory safety standards.

4. Are there opportunities for using biodegradable excipients in calcipotriol formulations?
Yes, biodegradable excipients can improve environmental profile and may meet emerging consumer preferences.

5. What role do excipients play in combination psoriasis therapies?
Excipients facilitate stable formulations that combine calcipotriol with corticosteroids or other agents, expanding treatment options.

---

References

[1] Grand View Research. (2022). Psoriasis Treatment Market Size, Share & Trends Analysis.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Topical Drug Products – Development Guidelines.
[3] European Medicines Agency. (2018). Reflection Paper on the Use of Excipients in Topical Products.